The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cytokeratin 19 fragment (CYFRA21-1) to predict the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) harboring EGFR mutation.
Kosuke Tanaka
No relevant relationships to disclose
Akito Hata
No relevant relationships to disclose
Reiko Kaji
No relevant relationships to disclose
Shiro Fujita
No relevant relationships to disclose
Jumpei Takeshita
No relevant relationships to disclose
Takeshi Matsumoto
No relevant relationships to disclose
Kazuya Monden
No relevant relationships to disclose
Kazuma Nagata
No relevant relationships to disclose
Kyoko Otsuka
No relevant relationships to disclose
Shigeki Nanjo
No relevant relationships to disclose
Ryo Tachikawa
No relevant relationships to disclose
Kojiro Otsuka
No relevant relationships to disclose
Michio Hayashi
No relevant relationships to disclose
Keisuke Tomii
No relevant relationships to disclose
Nobuyuki Katakami
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca; Chugai Pharma